Often the main problem is variable bowel habit - there is sometimes diarrhoea and other days constipation. This is the main symptoms of irritable bowel syndrome (IBS)...

Remicaide and Humira

Remecaide and Humira  (infliximab and adalimumab)

  • These drugs are antibodies that have been developed to remove one specific molecule responsible for causing inflammation – that is TNF or tumour necrosis factor.
    • This antibody binds specifically to TNF and renders it inactive.  The result is a rapid decrease in the inflammation in the bowel.
    • TNF is a major contributor to inflammation in the bowel but is also involved in other diseases, in particular in arthritis.
    • Infliximab and adalimumab are very effective treatment in Crohn's disease (also used in rheumatoid arthritis).
    • Infliximab is given by intravenous infusion. Adalimumab is given by subcutaneous injection


How effective is infliximab and adalimumab?

    • After one infusion about 70% of people with Crohn’s disease have had a good response.
      • 1/3 have complete resolution of all symptoms.
      • This effect is observed within 2 weeks.
    • The impressive part about the response to infliximab and adalimumab is the healing of the ulceration seen on colonoscopy.
      • Often the response to steroids and salicylates (5-ASA)seems reasonable but when the colon or small bowel is examined there is still significant ulceration (active disease).
      • Without mucosal healing there is still the chance of complications such as scarring and fistula (see Crohn's disease section).


  • The results for ulcerative colitis are less impressive but still useful
    • infliximab has an important role in the treatment of acute colitis (in-hospital treatment).


What about the longer term response?

    • Sustained response is possible with repeated treatments.
      • For infliximab this is an infusion every 2 months - there is a small “drop-off” in effect over time.
      • For adalimumab (Humira) this is a fortnightly subcutaneous injection (easy to learn how to self-administer)


    • maintenance treatment with Humira is now fully funded for selected patients with Crohn's disease.
    • Humira if funded for perianal fistula from Crohn's disease   - special criteria apply


  • The availability of infliximab depends on the local arrangements within each DHB.
    • Some patients with ulcerative colitis who have a good response to inpatient treatment will be able to continue with maintenance treatment
    • Other patients with ulcerative colitis who have not responded to other treatments may be able to access infliximab




What about side-effects?

    • There is a small risk of infusion reactions.
      • Allergic type reactions - at the time of giving the treatment.
      • This is usually just some flushing or dizziness.
      • The infusion is stopped for a short time and then is usually able to be completed without problems.


    • There has been a lot of concern about the possibility of infections.
      • TNF is an important part of the body’s defence against some infections.
      • In practice the risk of significant infections is about 2%.
      • There are recommendations to have a CXR and skin for TB - particularly if there is any even of previous exposure to tuberculosis.


  • There have been reports of an increased number of cases of lymphoma after infliximab treatment.
    • Longer term follow-up is very reassuring.
    • Infliximab and adalimumab have been widely used  for 10-15 years and the safety data has been very encouraging.



designed and developed by QT Web